Mayo Clinic study boosts Geron

Shares of Geron (GERN) are up 9% in premarket trading.

Behind the move looks to be an article outlining a Mayo Clinic study which says imetelstat "has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis."

The study's lead author calls the results "early but promising."

Amusingly, the article appears to have been posted ahead of its scheduled release from embargo.

Full article is here

Comments (1)
  • carlbatt
    , contributor
    Comment (1) | Send Message
    This isn't an article but a press release from the Mayo Clinic trying to promote attention to the presentation. It is standard operating protocol for most institutions who are attempting to draw attention to their work, from donors, alums or others.
    6 Dec 2013, 09:28 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs